Abstract:OBJECTIVE To study the reactivation of retinoic acid receptor beta (RARbeta) expression in myeloid leukemia cells by a combination of all-trans retinoic acid (ATRA) with a DNA demethylating agent, decitabine (DAC), and valproic acid (VPA, a histone deacetylase inhibitor),and their effects on cell differentiation and proliferation. METHODS Human myeloid leukemia cells of the line U937 were cultured and treated with all-trans retinoic acid (ATRA), DAC, and VPA. 72 h later cell differentiation test, cloning formation test, and chromatin immunoprecipitation test were performed. Bone marrow specimens were collected from 56 patients with acute myeloblastic leukemia (AML) were cultured and treated with and 10 bone marrow specimens were used as controls. Methylation of RARbeta promoter was detected with methylation specific polymerase chain reaction (MSP) after bisulfite treatment. Relative levels of RARbeta mRNA were assessed with real time quantitative PCR assay. Flow cytometry assay was used to detect the myeloid differentiation marker CD11b in U937 cells. Chromatin immuno-precipitation assay (ChIP) was used to analyze the acetylated histone 3 bound to the retinoic acid response element (RARE) at the promoter region of RARbeta. RESULTS Methylation of RARbeta was positive in 36 of the 56 (64.3%) AML patients and the U937 myeloid leukemia cells, however, was negative in the marrow mononuclear cells from the 10 healthy donors. The expression of RARbeta in U937 cells was up-regulated after treatment with ATRA (1 micromol/L) plus DAC (1 micromol/L) or VPA (0.5 mmol/L) for 72 hours, especially when the three drugs were used together. ChIP assay showed that the acetylated histone 3 bound to the RARE promoter region was increased after the cells were exposed to ATRA plus DAC/VPA. The data indicated that the reactivated expression of RARbeta might be secondary to the drug-induced histone acetylation as well as DNA demethylation. Treatment of U937 cells with ATRA and DAC/VPA also resulted in increased myeloid differentiation (CD11b expression) and decreased plating efficiency. CONCLUSION The repressed expression of RARbeta in myeloid leukemia cells is closely related to both DNA hypermethylation and histone deacetylation, and a combination of ATRA with epigenetic modulators can be beneficial in the treatment of myeloid malignancies.

Studies on the relationship between protein kinase C and differentiation of human promyelocytic leukemia cells induced by retinoic acid

Protein-Kinase-C in the Promyelocytic Leukemia-Cell Differentiation of Granulocytes

GW5074 and PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation

Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

Inhibition of all-trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells.

Loss of CAK phosphorylation of RAR{alpha} mediates transcriptional control of retinoid-induced cancer cell differentiation.

Chromosome Observations of Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid.

Intrinsic Retinoic Acid Receptor α-Cyclin-Dependent Kinase-Activating Kinase Signaling Involves Coordination of the Restricted Proliferation and Granulocytic Differentiation of Human Hematopoietic Stem Cells

The Ubiquitin-Proteasome Pathway Plays Essential Roles In Atra-Induced Leukemia Cells G(0)/G(1) Phase Arrest And Transition Into Granulocytic Differentiation

The AhR agonist VAF347 augments retinoic acid-induced differentiation in leukemia cells

Cytoplasm Prepared from All-Trans Retinoic Acid (Atra)-Treated Human Hematopoietic Progenitor Cells Induces Differentiation of Both ATRA Sensitive and ATRA Resistant Leukemia Cells.

Restoration Of Ccaat Enhancer Binding Protein Alpha P42 Overcomes Myeloid Differentiation Block And All-Trans Retinoic Acid Resistance In Human Acute Promyelocytic Leukemia Nb4-R1 Cells

Comparative Proteome Study of Apoptosis Induced by As4S4 in Retinoid Acid Resistant Human Acute Promyelocytic Leukemia NB4-R1 Cells

Significance of PLSCR1 in Matrine Induced Differentiation of ATRA Resistant APL Cells

Four years' experience with the treatment of all-trans retinoic acid in acute promyelocytic leukemia.

RBCK1‐TRIB3 decelerated the progression of acute promyelocytic leukemia

Comparative Proteomic Analysis of All-Trans-retinoic Acid Treatment Reveals Systematic Posttranscriptional Control Mechanisms in Acute Promyelocytic Leukemia

Role of eIF3a in 4-amino-2-trifluoromethyl-phenyl retinate-induced cell differentiation in human chronic myeloid leukemia K562 cells

CYTOKINE SECRETION IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA AFTER TREATMENT WITH ALL-TRANS RETINOIC ACID

ATPR-induced differentiation and G0/G1 phase arrest in acute promyelocytic leukemia by repressing EBP50/NCF1 complex to promote the production of ROS

[Epigenetic Regulation of Expression of Retinoic Acid Receptor Beta Gene in Leukemia Cell].